tetano
Editor, Senior Moderator
J Inflamm Res
. 2020 Jul 1;13:285-292.
doi: 10.2147/JIR.S257078. eCollection 2020.
Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)
Pourya Gholizadeh[SUP] 1 2 [/SUP], Rohollah Safari[SUP] 3 [/SUP], Parham Marofi[SUP] 4 [/SUP], Elham Zeinalzadeh[SUP] 4 [/SUP], Pasquale Pagliano[SUP] 5 [/SUP], Khudaverdi Ganbarov[SUP] 6 [/SUP], Silvano Esposito[SUP] 5 [/SUP], Ehsaneh Khodadadi[SUP] 7 [/SUP], Mehdi Yousefi[SUP] 8 [/SUP], Hossein Samadi Kafil[SUP] 7 [/SUP]
Affiliations
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) emerged in China and spread worldwide. In this study, we assessed the characteristics of markers of the liver in patients with COVID-19 to provide new insights in improving clinical treatment.
Patients and methods: We recruited 279 patients who confirmed COVID-19 and the data of liver biomarkers and complete blood count of patients were defined as the day onset when the patients admitted to the hospital.
Results: The average of LDH value was 621.29 U/L in all patients with COVID-19, and CPK was 286.90 U/L. The average AST was 44.03 U/L in all patients, and ALT was 31.14 U/L. The AST/ALT ratio was 1.64 in all patients. The measurement of CRP was increased by 79.93% in all patients. Average ALT and AST values of patients with elevated ALT were significantly increased in comparison to patients with normal ALT (P-value = 0.001), while AST/ALT ratio was significantly decreased compared to patients with normal ALT (P-value= 0.014). In addition, the average LDH of patients with elevated ALT was significantly increased compared to patients with normal ALT (P-value = 0.014).
Conclusion: Hepatic injury and abnormal liver enzymes related to COVID-19 infection is an acute non-specific inflammation alteration.
Keywords: COVID-19; SARS-CoV-2; aminotransferases; hepatic injury; liver enzymes.
. 2020 Jul 1;13:285-292.
doi: 10.2147/JIR.S257078. eCollection 2020.
Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19)
Pourya Gholizadeh[SUP] 1 2 [/SUP], Rohollah Safari[SUP] 3 [/SUP], Parham Marofi[SUP] 4 [/SUP], Elham Zeinalzadeh[SUP] 4 [/SUP], Pasquale Pagliano[SUP] 5 [/SUP], Khudaverdi Ganbarov[SUP] 6 [/SUP], Silvano Esposito[SUP] 5 [/SUP], Ehsaneh Khodadadi[SUP] 7 [/SUP], Mehdi Yousefi[SUP] 8 [/SUP], Hossein Samadi Kafil[SUP] 7 [/SUP]
Affiliations
- PMID: 32669866
- PMCID: PMC7335895
- DOI: 10.2147/JIR.S257078
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) emerged in China and spread worldwide. In this study, we assessed the characteristics of markers of the liver in patients with COVID-19 to provide new insights in improving clinical treatment.
Patients and methods: We recruited 279 patients who confirmed COVID-19 and the data of liver biomarkers and complete blood count of patients were defined as the day onset when the patients admitted to the hospital.
Results: The average of LDH value was 621.29 U/L in all patients with COVID-19, and CPK was 286.90 U/L. The average AST was 44.03 U/L in all patients, and ALT was 31.14 U/L. The AST/ALT ratio was 1.64 in all patients. The measurement of CRP was increased by 79.93% in all patients. Average ALT and AST values of patients with elevated ALT were significantly increased in comparison to patients with normal ALT (P-value = 0.001), while AST/ALT ratio was significantly decreased compared to patients with normal ALT (P-value= 0.014). In addition, the average LDH of patients with elevated ALT was significantly increased compared to patients with normal ALT (P-value = 0.014).
Conclusion: Hepatic injury and abnormal liver enzymes related to COVID-19 infection is an acute non-specific inflammation alteration.
Keywords: COVID-19; SARS-CoV-2; aminotransferases; hepatic injury; liver enzymes.